Biotechnology

Montreal deal also aims to provide critical financing to developing world; draft calls for raising $200 billion by 2030 for biodiversity, with a plan that could provide another $500 billion

Biotechnology major Biocon on Wednesday said it has initiated a clinical study in collaboration with Equillium Inc to evaluate efficacy of Itolizumab in patients with Ulcerative Colitis. This is a phase two randomised, double-blind, parallel-group, placebo and active-controlled (adalimumab), two treatment period study to evaluate the safety and efficacy of Itolizumab for the induction of remission in biologics naive patients with moderate to severely active Ulcerative Colitis (UC), Biocon said in a statement. Having obtained approval from the Drugs Controller General of India (DCGI), the study will cover several tertiary hospitals specialised in handling UC cases, it added. The first patient who intended to participate in the study was screened on December 1, 2022, the company said. "The commencement of the Phase two clinical study, that will determine its efficacy for the treatment of Ulcerative Colitis, is an important step forward in our efforts to bring its benefit to patients

FSSAI has come out with draft regulations for genetically modified food, proposing mandatory prior approval from the regulator to manufacture, sell and import food or ingredients produced from genetically-modified organisms. The proposed Food Safety and Standards (Genetically Modified Foods) Regulations, 2022 will apply to Genetically Modified Organisms (GMOs) intended for food use, as per the Food Safety and Standards Authority of India (FSSAI). The regulations, once implemented, will also be applicable to food ingredients produced from GMOs that contain modified DNA as well as for food ingredients produced from GMOs that do not contain modified DNA but includes ingredients/additives/processing aids derived from GMOs. GMO means any living organism that possesses a novel combination of genetic material obtained through the use of modern biotechnology. "No person shall manufacture, pack, store, sell, market or otherwise distribute or import any food or food ingredient produced from

Firm is develop recombinant products in hormones, eyes acquisitions in South East Asia

First crop to get such recommendation since Bt cotton in years, say experts

Amid the surge in the new and recombinant variants, scientists across the world are now watching out for variants which could turn into variants of concern soon

Pre-clinical trials show no evidence of side effects in the product, which is the ninth such to be developed from marine organisms by Kochi-based CMFRI

JMI UG admission 2022 to begin from September 26. Candidates can visit the official website for further updates

The company will introduce CREST Diving to DRDO's DEBEL and will aim to make India an alternative to China as a manufacturer of dive equipment

"We are now getting to 'wet' pathology tests like blood tests etc and we have set up a centre which will have minimal human intervention and maximum automation

Biotechnology major Biocon on Wednesday reported a 71 per cent increase in consolidated net profit at Rs 144 crore for the June quarter on the back of robust growth across business verticals. The company had posted a net profit of Rs 84 crore in the April-June quarter of the previous fiscal. Total revenue rose to Rs 2,217 crore in the first quarter as compared with Rs 1,808 crore in the year-ago period, Biocon said in a regulatory filing. Biocon Executive Chairperson Kiran Mazumdar-Shaw said revenues grew as a result of robust growth in both biosimilar and generics verticals. "Our financial performance this quarter includes the impact of annual increments in personnel costs as well as increased input and freight costs, pursuant to pandemic and geopolitical disruptions of global supply chains," she added. All the company businesses are poised for the next phase of sustainable growth which has been challenged during the two years of the Covid pandemic, Mazumdar-Shaw said.

Two decades after Bt cotton made its debut in India, commercialisation of genetically modified crops remains mired in complex procedural rules

Highlighting the potential of bio start-ups in India, Narendra Modi on Thursday said India's diverse population and climatic zones are among the top factors behind the growth of the biotech industry.

Jammu and Kashmir (J&K) Lieutenant Governor, Manoj Sinha and Union minister Jitendra Singh on Saturday inaugurated the north India's first Industrial Biotech Park constructed at Ghatti near Kathua.

Samsung promised in a statement to create 80,000 jobs through 2026, mostly in semiconductors and biopharmaceuticals.

Biocon Biologics is a subsidiary of Biocon Ltd

Indian-American Congressman Ro Khanna was on Thursday named to the National Security Commission on Emerging Biotechnology

The company in a statement said that its subsidiary Biocon Biologics has inked a pact to acquire Viatris Inc's biosimilars business for consideration of up to USD 3.335 billion

The vaccine maker's COVID-19 shots, which are now available in more than 70 countries, totalled USD 17.7 billion in sales last year, their first full year on the market

CM Bhupendra Patel unveiled a new biotechnology policy for the next five years that seeks to make Gujarat one of the leading states in the country in the key sector